shutterstock_1913714050

The Best Keosys Blogs of 2022

Keosys
Recap: Top blog posts of 2022


It’s been a great year for Keosys, the advancement of medical imaging technology, and clinical trial innovation in oncology. There’s a lot to be excited about, so we’ve compiled our list of our most-viewed blog posts of the year so you can reflect on expert interviews, key studies, and more. Enjoy!

 
Interview: A Clinical R&D Expert Talks About the Future of Radiopharmaceuticals

This summer, we spoke with Dan Stevens, the VP of Clinical Development and Medical at Blue Earth Therapeutics, about his outlook on the future of radiopharmaceutical therapies in oncology. Our conversation covered a wide range of topics, including clinical trial management, development challenges, and how radiopharmaceuticals can improve the future of patient care.

Read the conversation now.

 

Prostate Cancer Working Group 3: Imaging Assessments Infographic

To summarize the guidance of the Prostate Cancer Working Group 3, we created an infographic with all of the essential key points for subject imaging assessments in prostate cancer clinical trials. PCWG3 is an international working group of experts working to move drug development closer to unmet clinical needs.

Get the resource.

 

Interview: A Radiology Professor Talks About mRECIST, Reading Images in Clinical Trials, and More

Maxime Ronot is a professor at the Université de Paris, a central reader for Keosys, and a radiologist in the Department of Medical Imaging at the Beaujon University Hospital in Clichy, France. We spoke with Professor Ronot, who has worked with Hepatocellular Carcinoma since 2008, about using mRECIST in HCC treatment and his work as in academia.

Read now.

 

Interview: An Interventional Radiologist Talks About Radioembolization in the Treatment of HCC Today

Dr. Yan Rolland is the head of the diagnosis and interventional radiology department at Centre Eugène Marquis, in Rennes, France. For more than 30 years, Dr. Rolland has been working to improve the treatment of hepatocellular carcinoma. Catch up on our conversation about industry insights, his career, radioembolization, and more.

Relive the conversation.

 

Deformable Image Registration with Deep Network Priors: A Study on Longitudinal PET Images

To help physicians monitor all lesions and evaluate tumor evolution more accurately, research has notably focused on image registration methods. PET images acquired at different time points are precisely registered, and can make the assessment of all lesions become much easier. We proposed a new registration method, called MIRRBA.

Learn more. 

 

Looking forward to a new year

Each passing year brings new and exciting innovation. 2023 will be no different, and we look forward to helping you achieve your goals to make a real, significant change to improve patient outcomes.

Are you ready to make an impact in 2023? Contact us today.

 

 
New call-to-action

More Posts

New call-to-action